ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
In plain words A Phase 2 study of alpha-Linolenic Acid in people 60 and older, run by Michal Schnaider Beeri, Ph.D.. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older; healthy volunteers accepted. Conditions: Cognitive Dysfunction; Alzheimer Disease; Blood-Brain Barrier; Apolipoprotein E, Deficiency or Defect of; Brain Aging; Fatty Acids, Omega-3.
- Age 60 years or older
- Have amnestic Mild Cognitive Impairment (MCI) - memory problems that do not interfere with daily life.
- Carry at least one APOE4 gene allele (determined by a blood test).
- Be fluent in English or Spanish.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Alpha-Linolenic Acid (2.6 g/day); Placebo Control Group
Registered summary
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. The full summary is on the listing.
Where, as registered
1 US site in 1 state.